Co-morbidity and cardio-metabolic risk factors in patients with osteoarthrosis
Abstract
Aim. To study co-morbidity prevalence, as well as metabolic effects on atherosclerosis progression and cardiovascular risk, in patients with osteoarthrosis (OA).
Material and methods. In total, 83 patients with confirmed OA diagnosis (American College of Rheumatology criteria). The age of participants was 45-70 years (mean age 58,35+12,5 years), and OA duration was 1-24 years (mean duration 9,8±4,7 years). The examination included pain syndrome assessment with visual analog scale (VAS), calculation of WOMAC (Western Ontario and McMaster Universities) index and body mass index (BMI), measurement of waist and hip circumference (WC, HC) and WC/HC ratio. Joint ultrasound examination (Phillips HD-11) was used to assess periarticular tissue status and visualise articular cartilage and bone surfaces. Serum levels of C-reactive protein (CRP) and interleukin-6 (IL-6) were measured by immune-enzyme method.
Results. Obesity was diagnosed in 51 OA patients (67,64%). These participants demonstrated higher synovitis prevalence, higher values of algo-functional indices, and elevated IL-6 and CRP levels, as well as higher frequency of cardiovascular disease and cardiovascular events in anamnesis.
Conclusion. In OA patients, obesity was more prevalent. Compared to those with BMI<30 kg/m2, obese individuals with OA showed higher levels of triglycerides and CRP, lower concentration of high-density lipoproteins, and higher prevalence of Caro index <0,33 (insulin resistance marker). Therefore, the combination of OA and obesity was characterised by clustering of cardiovascular risk factors.
References
1. Насонова В. А. Проблема ОА в начале XI века. Cons Med 2000; 2(6): 244-8.
2. Dahaghin SM, Dierma-Zeinstra A. Do metabolic factors add to the effect of overweight on hand osteoarthritis? The Rotterdam Study. Annals of the Rheumatic Dis 2007; 66: 916-20.
3. Adler A, Stratton IM, Neil H, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational stady. BMJ 2000; 321:412-9.
4. Ciccutini FM, Teichtahl AJ, Weuka AF, et al. The relationship between body composition and knee cartilage volume in healthy middle-aged subjects. Arthr & Rheumat 2005; 52(2): 461-7.
5. Lau DC, Dhillon B, Yan H, et al. Adipokines: Molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol 2005; 288(5): 2031-41.
6. Dandona P, Aljada A, Chaudhury A, et al. Metabolic Syndrome: A Comprehensive Perspective Based on Interactions Between Obesity, Diabetes, and Inflammation. Circulation 2005; 111: 1448-54.
7. Метаболический синдром. Под ред. чл.-корр. РАМН Г.Е.Ройтберга. Москва “МЕД-пресс-информ” 2007; 83-103.
8. Aspden RM, Scheven BA, Hutchison JD. Osteoarthritis as a systemic desorder including stromal cell differentiation and lipid metabolism. Lancet 2001; 7; 357 (9262): 1118-20.
9. Зубарев А.В. Диагностический ультразвук. Костномышечная система. Москва, ООО “Фирма Стром” 2002; 136 с.
10. Fasshauer M, Paschke R, Stumvoll M. Adiponectin, obesity, and cardiovascular disease. Biochemicie 2004; 86(11): 779-84.
11. Felson DT, Goggins J, Niu J, et al. The effect of body weight on progression of knee osteoarthritis is dependent on aligment. Arthritis Rheum 2004; 50(12): 3904-9.
12. Wellen K, Hotamisligil G. Inflammation, stress, and diabetes. J Clinic Invest 2005; 115: 1111-9.
13. Eckel RH. Obesity and metabolic syndrome. Lancet 2005; 365: 1415-28.
14. Behre CJ, Fagerberg B. The reciprocal association of adipocytokines with insulin resistance and C-reactiv protein in clinically healthy men. Metabolism Clin Exper 2005; 54: 439-44.
15. Митьков В.В. Клиническое руководство по ультразвуковой диагностике. Москва “ВИДАР” 1997; 6: 388 с.
16. Edward TH. CPB as a Mediator of Disease. Circulation 2004; 109: 2211-4.
17. Kumar N, Marshall NJ, Neely D, et al. CRP levels are raised in patients with longstanding osteoarthritis when compared with normal controls. Rheumatology 2004; 43(Suppl. 2): 69.
18. Ridker PM, Wilson P. Should C-Reactive Protein Be Added to Metabolic Synrome and to Assessment of Global Cardiovascular Risk? Circulation 2004; 109: 2818-25.
19. Lyon CJ, Law RE, HsuehWA. Minireview: Adiposity, Inflammation, and Atherogenesis. Endocrinology 2003; 144(6): 2195-200.
20. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulatioon 2002; 105: 2696-8.
21. Clay F. Semenkovich. Insulin resistance and atherosclerosis. J Clin Invest 2006; 116(7): 1813-21.
22. Pincus T, Sokka T. Abstract presented during the American College of Rheumatology 2005 Scientific Sessions. San Diego, California.
23. Ruotolo G, Howard B, Robbins D. Dislypidemia of obesity2003. Chapter 10.
24. Fernandes-Real JM, Ricart W. Insulin resistance and Chronic Carrdiovascular Inflammatory Syndrome. Endocrine Rev 2003; 24(3): 278-301.
25. Hanter DJ, Nin J, Zhang G, et al. Knee height, knee pain and knee osteoarthritis. Arthritis & Rheumatism 2005; 52(5): 1418¬23.
26. Dandona P, Aljada A, Chaudhury A, et al. Metabolic Syndrome: A Comprehensive Perspective Based on Interactions Between Obesity, Diabetes, and Inflammation. Circulation 2005; 111: 1448-54.
27. Grundy SM. Inflammation, Hypertension, and Metabolic Syndrome. JAMA 2003; 290(22): 2945.
28. Haffner SM, Cassells HB. Metabolic syndrome — a new risk factor of coronary heart disease. Diabetes, Obesity and Metabolism 2003; 5: 359-70.
29. Шевченко О.П., Праскурничий Е.А., Шевченко А.О. Метаболический синдром. Москва “Рефарм” 2004; 141 с.
30. Rocchini AR. Obesity Hypertension. Am J Hypert 2002; 15: 50S-2.
Review
For citations:
Artemenko N.A. Co-morbidity and cardio-metabolic risk factors in patients with osteoarthrosis. Cardiovascular Therapy and Prevention. 2009;8(4):45-51. (In Russ.)
Views:
494
Email this article 
